Janak Adhikari

[Janak Adhikari @jaannak]

https://t.co/JGjcywzKLG

[Tony Breu @tony_breu]

1/14
Why can't you use direct oral anticoagulants (DOACs) in patients with mechanical valves (MVs)?

DOACs have been one of the most important advances in my career. And yet, the presence of a MV is one of the few contraindications.

The reason highlights the unique nature of thrombus formation in those with a MV and provides insights into the evolution of human hemostasis.

[Dr. Hardik Patel 🩺💉 @hardik4u24]

🩺Diagnosis and Mx of AKI on immune checkpoint inhibitors?

🔪When to biopsy?
💉 Steroid or spare?
💊Mycophenolate vs infliximab?

#OncoNephrology 🦀
@HerrmannMd

#AKI #ImmuneRelatedAE #NephTwitter #Nephrology #MedX

📖 https://t.co/dJelyjULv2 🆕

[Dr. Hardik Patel 🩺💉 @hardik4u24]

🧬🔬Renal biopsy says amyloidosis… what next?

This brilliant IHC-based algorithm 🔁 guides you through AL, AA, & rare amyloid types—don’t miss that dual diagnosis!

🔗 https://t.co/PiJMb1tIyb 🆕
Dr @VinitaSGPGIMS et. al

#RenalPath #Amyloidosis #Nephrology #MedTwitter

[VR.Krishnakumar @KKNephBytes]

SGLT2i Pleiotropic Effect Key notes
#SGLT2 #CKD #progression @divyaa24 @DrSumanBehera @happiedoc @priti899 @hardik4u24 @

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Hypokalemia: Diagnostic algorithm
#Nephpearls

☑️ Urine K
☑️ Serum Mg
☑️ Serum CO2
☑️ Blood Pressure
☑️ Urine Chloride
☑️ Renin, Aldosterone

👉 https://t.co/gHPlf8Cvrr

[Sanjeev Sethi @SethiRenalPath]

Simple concept of GN. It’s all about location!

1. Subendothelial deposits/injury by Ig, immune-complexes, complement, other mechanism leads to influx of leukocytes= inflammation=GN

2. Subepithelial deposits/injury= protected by GBM & endothelial cells=no inflammation=No GN. 1/3

[AJKD @AJKDonline]

Core Curriculum by @captainchloride and @SarahSanghavi:

Disorders of Volume: Core Curriculum 2025

https://t.co/nVx1unT6yN (FREE)

[Dr. Hardik Patel 🩺💉 @hardik4u24]

Hyperkalemia workup simplified🧪

TTKG tool helps assess distal nephron K+ secretion & aldosterone response

💡If TTKG <6, think aldosterone issues. Post-fludrocortisone rise? It’s hypoaldosteronism!

🔗https://t.co/H1ZNkYRAsp

#TTKG #Hyperkalemia #AJKD 2025 #Nephrology #MedEd

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Resistant Hypertension in CKD ca. 2011 from @MRrenaldoc @CJASN
#Nephpearls

👉 https://t.co/YkhlCJk1F3

[Kenar Jhaveri @kdjhaveri]

The Difficulties of Treating Complement-3-Mediated Glomerulopathy https://t.co/7qeAECCxBs

[Kenar Jhaveri @kdjhaveri]

Tweetorial on MTX related renal toxicity @onconephsociety @ASCO @ASH_hematology @BloodCancerJnl -- See below to start!

[sganguly @bmtdoc63]

Ifosfamide
Can cause encephalopathy especially in patients with hypoalbuminemia. IV albumin prophylaxis. IV methylene blue treatment.
Ifos can cause Type II RTA with NAG acidosis, hypokalemia, hypophosphatemia & Fanconi type proteinuria and glucosuria. MESNA cannot prevent this.

[Talha Badar @TalhaBadarMD]

#weekend_review #ALL #blinatumomab #Inotuzumab🧵
1/ Introduction to B-cell ALL, risk stratification and treatment algorithm for #hemonc_fellows #MedTwitter #hemonctrainees

[Hagop Kantarjian,MD @DrHKantarjian]

All you need to know about the latest JAK inhibitor to be approved for myelofibrosis in this concise review in @BloodJournal by @Bose_Prithviraj of @MDAndersonNews #Leukemia
https://t.co/bPGTTunNJD
#MPNsm

[Vijaya R Bhatt, MBBS, MS @VijayaRBhatt1]

📢Results of our multicenter study! @HematologistMD @StephanieLeeMD @nishihori https://t.co/rZUieiU26G @UNMCHemeOnc
@UNMC_IM
@unmc_research

[Wiley Clinical and Health @WileyHealth]

A recent study published in @JournalCancer reveals that deaths from advanced #LungCancer have dropped significantly since #immunotherapy became standard-of-care.

The findings are covered by @medical_xpress: https://t.co/mXa3gSv2Yh

@DipeshUpretyMD @YatingWang885 @jaannak

[Janak Adhikari @jaannak]

https://t.co/XCkz51je09

[Janak Adhikari @jaannak]

@VijayaRBhatt1 @unmc @UNMC_IM @UNMCHemeOnc Congratulations dai

[Vincent Rajkumar @VincentRK]

Just out: My 2024 Update on diagnosis, risk stratification, and treatment of myeloma.
#AJH @MayoCancerCare

10 Tables; Algorithms
Includes current data including trials published this month! #ASCO24

https://t.co/B9nLdpfbLK

[Talha Badar @TalhaBadarMD]

#EHA2024 #EHA24 #MPN #mpnsm

Skoda: clonal evolution of MPN, pre-CHIP—> CHIP—>MPN

1) concurrent mutation e.g. DNMT3A confer resistance to therapy

2) pegIFN most efficient way to decrease mutation allelic burden in MPN

3) pegIFN in combination with AZA may overcome concurrent resistant mutation in MPN